Thalia Therapeutics advances RNA therapy programs

Thalia Therapeutics plc has reported significant progress in its RNA-based therapeutics development programs, including the continuation of a Phase 1 dose-escalation clinical trial for miRisten in patients with relapsed or refractory Acute Myeloid Leukemia (AML). The therapy, which inhibits microRNA-126 to target leukemia stem cells, is being developed for AML, a condition that affects over 22,000 new U.S. patients annually.

Additionally, Thalia has commenced preclinical development of THAT-002, a bispecific siRNA cardiovascular program targeting PCSK9 and lipoprotein(a), with plans for IND-enabling non-human primate studies in early 2027. The company has also appointed Luke Cairns as Chief Financial Officer and completed a rebranding and acquisition in July 2026, along with a £2.75 million fundraise.

Thalia will provide an update on its interim results for the six months ended June 30, 2026 on September 30.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.